Experience on rhino-orbital mucormycosis from a tertiary care hospital in the first wave of COVID-19: An Indian perspective

Gunjan Saluja a, Anju Bharia a, Neelam Pushker b, Sahil Agrawal c,*, Rachna Meel b, Alok Thakar d, Immaculata Xesse e, Ankur Khandelwal f, Anubhav Narwal g, Mandeep S. Bajaj b

a Senior Resident, Oculoplastics, Tumor & Pediatric Ophthalmology Services, Dr R. P. Centre for Ophthalmic Sciences, AIIMS, New Delhi, India
b Professor, Oculoplastics, Tumor & Pediatric Ophthalmology Services, Dr R. P. Centre for Ophthalmic Sciences, AIIMS, New Delhi, India
c Senior Research Officer, Oculoplastics, Tumor & Pediatric Ophthalmology Services, Dr R. P. Centre for Ophthalmic Sciences, AIIMS, New Delhi, India
d Professor (Otolaryngology), AIIMS, New Delhi, India
e Professor (Microbiology), AIIMS, New Delhi, India
f Senior Resident (Anaesthesia), AIIMS, New Delhi, India
g Senior Resident (Pathology), AIIMS, New Delhi, India

ABSTRACT

Background: To highlight the clinical presentations and management outcomes of rhino-orbital mucormycosis during first wave of COVID-19 pandemic in North India.

Methods: A retrospective observational study. 15 patients with mucormycosis (orbital disease) who presented during short span of 3 months (October–December 2020) in a tertiary-care referral institution were analysed.

Results: At presentation, 13 of 15 patients had uncontrolled diabetes. Four had history of COVID-19 infection. All patients had advanced orbital disease with sinusitis; cavernous sinus involvement was in nine and intracranial spread in three patients. Liposomal amphotericin-B was started and prompt orbital exenteration with sinus surgery was performed in 12 patients. All 12 patients survived with an average follow-up of 4.8 months.

Conclusion: In the present series, cases with orbital spread of mucormycosis were mostly found in non-COVID uncontrolled diabetics. Exenteration was done in 80% of cases with advanced orbital disease. Prevention and early detection of infection at the stage of sinonasal involvement might help to prevent spread and/or halt the orbital disease.

© 2022 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd. All rights reserved.
Introduction

Orbital mucormycosis or zygomycosis is an aggressive and necrotising form of fungal infection that usually occurs secondary to the infection of the nasal cavity and paranasal sinuses. It is caused by mould fungus of order Mucorales, genera Rhizopus sp. and Mucor sp. commonly by the former. In the pre-COVID era, the reported overall incidence of orbital mucormycosis amongst diabetics was 0.15%. Immunocompromised condition such as severe neutropenia, haematological malignancies, and chronically debilitating disease can also predispose patients to fungal infection. Rhino-orbital–cerebral mucormycosis (ROM) has been the most frequent (55.6%) form of presentation. During the first wave of the COVID-19 pandemic, immediately after the surge in the number of cases in North India, we noticed a sudden increase in the number of cases admitted to our hospital with the orbital spread of mucormycosis. We hereby, report the clinical features, and management outcomes in 15 cases of ROM, managed at our institute, for 3 months (October–December, 2020). We also reviewed the literature on COVID-19, and ROM published in the literature.

Materials and methods

This is a retrospective observational study of patients with orbital spread of mucormycosis who presented at our institute from October to December, 2020, immediately after the peak of COVID-19 cases in North India. Written informed consent was obtained and the study was conducted following the Declaration of Helsinki. Institute ethics committee approval was obtained. All tissues were sent for microbiological and histopathological studies. On direct microscopy, patients who showed the presence of broad, aseptate hyphae with right angle branching and/or twisted, ribbon like hyphae were included in the study. Data was collected and analysed for age, gender, clinical presentation, history of COVID-19, imaging features, and management outcomes. A literature search was done on PubMed using keywords, orbital mucormycosis, ROM, COVID-19, corona infection.

Results

Basic demographics and clinical history

In the study period, 15 patients with proven ROM were recruited of which twelve patients were males, and three were females. The mean age of presentation was 43.9 ± 18.1 years (range 14–66 years). Out of 15 patients, 13 had a history of diabetes mellitus of which two patients (cases 4 & 5) were diagnosed with diabetes mellitus on admission. All the 13 patients had uncontrolled diabetes with high levels of HbA1c (range 8.5–15.5%) with 2 patients (cases 8 & 10) also had diabetic ketoacidosis. Case 9 had acute lymphoblastic leukaemia and was on oral steroids for the past three years and the other patient (case 12) had a recent history of acute hepatitis A. Of all the patients four (cases 4, 11, 12, & 15) had a history of COVID-19 infection, following which they developed features of mucormycosis within 10–15 days of onset of infection. Of these patients, three (cases 4, 11, & 15) had a history of steroid use for the management of the COVID-19 infection. KOH-calcofluor white stain performed on the nasal biopsy was found to be positive for aseptate hyphae in 14 of 15 patients. In one patient (case 13), due to repeated negative nasal biopsies, the orbital biopsy was performed, which was positive for aseptate hyphae. In one patient (case 7), both septate and aseptate hyphae on KOH-calcofluor white stain was present, but culture had the growth of Aspergillus sp. only. Rhizopus was reported in one patient (case 1) and fungal culture report was negative in five cases.

Clinical features at presentation (Table 1)

The mean duration of ocular symptoms was 10.4 ± 2.2 days (range 5–25 days). At presentation, 12 of 15 patients were systemically stable; two patients required ventilator support (cases 8 & 10) and one patient (case 7) had hemiplegia. Out of 15 patients, twelve had a visual acuity of no perception of light. In one patient (case 9), visual acuity was 20/80. Moderate to severe proptosis, ptosis, total ophthalmoplegia, conjunctival congestion, and chemosis, were the presenting signs in all the patients except two patients with advanced disease who were on ventilator and assessment of ocular motility, ptosis, and visual acuity could not be done. The retropulsion test was significantly positive in all the patients. The cornea was clear in 13/15 patients. Central retinal artery occlusion was found in 12/15 patients. In two patients (cases 10 & 7), fundus could not be assessed because of corneal haze. Case 7 developed pan ophthalmitis, seven days following wound dehisence of small incision cataract surgery, thereafter he developed proptosis.

Imaging at presentation

Contrast-enhanced imaging revealed the presence of proptosis with diffuse orbital soft tissue involvement till the apex in 14 patients. There was predominantly medial orbit involvement in one patient (case 8). Globe tenting was present in three patients (cases 1, 2, & 6) suggestive of extensive involvement of the orbital tissues. Cavernous sinus thrombosis was found in nine patients (cases 1, 2, 4, 7–10, 12, 15). Pansinusitis was present in 14/15 patients. Case 13 had maxillary and ethmoid sinusitis. Involvement of the central nervous system was present in three patients (Cases 7, 8, & 10). Fig. 1A–D & 2A-B; shows the clinical presentation and imaging characteristics of some of our cases.

Management

In view of proven ROM, all the patients were admitted and started with intravenous liposomal amphotericin B. A multidisciplinary surgical approach was planned in every case involving an otolaryngologist and an oculoplastic surgeon. Orbital exenteration along with sinus debridement was performed in 12 patients. In addition, maxillectomy was performed in four patients and ethmoidectomy in one patient, depending upon the extent of bone necrosis. Histopathology
| Case, No., age/sex | Visual acuity | Eye involved | Clinical features at presentation | Predisposing factors | Surgery performed | Survival outcome/last FU |
|-------------------|---------------|--------------|-----------------------------------|----------------------|-----------------|--------------------------|
| 14/M              | No PL         | R            | P, CC, TO, R - positive, CRAO     | DM for 5 years       | Exenteration, sinus debridement with maxillectomy | Survived, 5 months |
| 35/M              | No PL         | R            | P, CC, TO, R- positive, CRAO      | DM for 2 years       | Exenteration, sinus debridement with maxillectomy | Survived, 6 months |
| 38/M              | No PL         | R            | P, CC, TO, R- positive, CRAO      | DM for 8 years       | Exenteration with sinus debridement               | Survived, 6 months |
| 45/F              | No PL         | R            | P, CC, TO, R- positive, CRAO      | DM for 10 days       | Exenteration with sinus debridement               | Survived, 5 months |
| 26/M              | No PL         | L            | P, CC, TO, R- positive, CRAO      | DM for 15 days       | Exenteration, sinus debridement with ethmoidectomy | Survived, 5 months |
| 56/F              | No PL         | R            | P, CC, TO, R- positive, CRAO      | DM for 3 years       | Exenteration, sinus debridement with maxillectomy | Survived, 5 months |
| 64/M              | No PL         | R            | P, CC, TO, R- positive, pan ophthalmitis | DM for 18 months     | Exenteration, sinus debridement with maxillectomy | Survived, 4 months |
| 53/M              | Vision could not be assessed | R | P, CC, R- positive, CRAO | DM for 8 years       | Surgery deferred as the patient was on ventilator; Intra-orbital amphotericin 8 injections given | Death due to multi-organ failure on day 16 |
| 59/F              | 20/80         | R            | P, CC, R- positive               | ALL on steroids for 4 years | Surgery deferred because of low platelet counts | Death on day 21 due to rapid progression of infection |
| 66/M              | Vision could not be assessed | L | P, CC, Corneal haze, R-positive | DM for 8 years       | Surgery deferred as patient was on ventilator | Death on day 7 |
| 55/M              | No PL         | L            | P, CC, TO, R- positive, CRAO      | DM for 12 days, COVID-19 | Exenteration with sinus debridement               | Survived, 4 months |
| 28/M              | No PL         | R            | P, CC, TO, R- positive, CRAO      | Hepatitis A, COVID-19 | Exenteration with sinus debridement               | Survived, 6 months |
| 32/M              | No PL         | R            | P, CC, TO, R- positive, CRAO      | DM for 5 years       | Exenteration with sinus debridement               | Survived, 4 months |
| 34/M              | No PL         | R            | P, CC, TO, R- positive, CRAO      | DM for 4 years       | Exenteration with sinus debridement               | Survived, 4 months |
| 61/F              | No PL         | R            | P, CC, TO, R- positive, CRAO      | DM for 2 years, COVID-19 | Exenteration with sinus debridement               | Survived, 4 months |

M, male; F, female; PL, light perception; R, right; L, left; P, proptosis; CC, conjunctival congestion & chemosis; TO, total ophthalmoplegia; R, retropulsion test; CRAO, central retina artery occlusion; DM, diabetes mellitus; ALL, acute lymphoblastic leukaemia; FU, follow-up
revealed extensive tissue necrosis, angioinvasion, presence of inflammatory cells, and fungal hyphae consistent with mucormycosis (Fig. 3A–D). In three patients, surgical intervention could not be performed as patients were systemically unstable, of which 1 patient (case 8) received injection amphotericin B in the medial orbit as the disease was predominantly in the medial orbit. Seven intra-orbital injections of amphotericin B in a dose of 3 ml (1 mg/ml) were given for 14 days.6

**Outcomes**

All patients who underwent prompt and aggressive surgical intervention, with systemic control of the underlying condi-
tion survived till mean follow up of 4.8 ± 0.83 months (range 4–6 months). However, three of our patients (cases 8, 9, & 10) could not survive due to the rapidly progressive disease and succumbed to the infection. Intravenous liposomal amphotericin was administered for a period of approximately 3–4 weeks, depending on the systemic tolerance. Thereafter, patients were switched to oral posaconazole treatment after stabilisation of infection. Oral posaconazole 300 mg twice a day for two doses, then 300 mg once daily was started for 4–7 days till the serum levels of posaconazole reached > 0.7 ug/mL. Thereafter, the injection of amphotericin B was stopped. Patients were discharged on oral posaconazole.

Discussion

Through this communication, we would like to highlight the emergence of a new and fatal enemy of immunocompromised patients especially uncontrolled diabetics during the first wave of the COVID-19 pandemic from an Indian perspective. In a case series, reported from India during the pre-COVID era, 11 cases were reported over four years, on the contrary, in our case series, 15 cases with orbital spread were encountered within a short span of three months. In the present study, the mean age of patients was 43.9 ± 18.1 years with male predominance. The majority of our patients (86.7%) were uncontrolled diabetics. Four (26.7%) patients had a history of recent COVID-19 infection with the use of steroids in three (20%) patients for management. On PubMed search, we found three case series of 6, 10, and 31 patients, respectively, from cases presented during the first wave of COVID-19, reported in ophthalmic literature from India. Sen et al. reported a series of six patients, with mean age, 60.5 ± 12 years, all were male patients. Of these, five patients had a recent history of uncontrolled diabetes with COVID infection, treated with steroids and one had concurrent COVID infection with diabetes, at presentation. Four patients had other co-morbidities also. Sarkar et al. reported a case series of 10 patients of ROM with COVID diagnosed on routine screening. The mean age was 45.5 years (range 23–67 years) with male predominance. All patients were known cases of diabetes mellitus with ketoacidosis in four patients. All except one patient, were on mechanical ventilation. Ravani et al. recently reported the largest case series of 31 patients with ROM. The mean age of patients was 56.3 years, with male predominance. The major risk factors reported were uncontrolled diabetes (96.7%), and COVID19 positivity (61.2%) with concomitant steroid use in 61.2% of patients. The clinical and/or imaging data of cases studied in the reported case series on ROM is limited. Further, in the largest reported case series, the outcome data related to ophthalmic features are not available.
| Parameters                                      | Present study | Sen et al., 2021<sup>10</sup> | Sarkar et al., 2021<sup>11</sup> | Ravani et al., 2021<sup>12</sup> |
|-----------------------------------------------|---------------|-------------------------------|-------------------------------|---------------------------------|
|                                               | Total pts – 15; (n) | Total pts – 6; (n) | Total pts – 10; (n) | Total pts – 10; (n) |
| Vision (No PL)                                 | 80% (12)<sup>a</sup> | 83.3% (5) | 50% (4 of 8) | 25.8% (8) |
| Proptosis                                      | 100% (15) | 83.3% (5) | NA | 25.8% (8)<sup>b</sup> |
| Ophthalmoplegia                                | TO – 80% (12) | TO – 83.3% | NA | 77.4% (24)<sup>b</sup> |
| CRAO                                          | 80% (12) | NA | 60% (6) | 6.45% (2) |
| Imaging findings of orbital disease           | Diffuse orbital involvement till apex – 14; medial orbital involvement – 1; Globe tenting – 3 | Extracranal involvement – 50% (5)<sup>c</sup> | Orifal cellulitis – 61.3% (19)<sup>c</sup>; EOM involvement – 19.4% (6); Optic neuritis – 9.7% (3); Bony orbital wall erosion – 6.5% (2); | |
| Orbital apex involvement                       | 93.3% (14) | 33.3% (2) | 50% (5) | NA |
| Cavernous sinus involvement                    | 60% (9) | 66.6% (4) | 10% (1) | 3.22% (1) |
| Pansinusitis                                   | 93.3% (14) | Sinusitis present in all patients but details NA | 60% (6) | 77.4% (24) |
| Cerebral involvement                           | 20% (3) | Exenteration – 33.3% (2); FESS – 100% (6) | 10% (1) | 22.5% (7) |
| Surgery performed                              | Exenteration – 80% (12); Sinus debridement (12) with maxillectomy (4) & ethmoidectomy (1); not fit for surgery – 20% (3) | Exenteration – 10% (1); maxillectomy – 40% (4); FESS with debridement (site – NA)– 20% (2); not fit for surgery – 30% (3); on mechanical ventilation – 90% (9) | Exenteration – 100% Orbital debridement done but data on the number of patients and extent of debridement – NA | |
| Clinical ophthalmic outcome                    | Socket healing present in all cases | Eye salvage – 66.7% (4); vision salvage – no patient | Unchanged status – 40% (4); improved – 10% (1) | NA |
| Survival                                       | 80% (12) | 100% | 60% (6) | 90.32% (28) |
| Follow-up                                      | 4–6 months | 0.3–3 months | 1 month | Minimum – 75 days in all the patients |

<sup>a</sup> Two cases could not be assessed, case 9–20/80.  
<sup>b</sup> Severity not mentioned.  
<sup>c</sup> Location and extent not available.
In April 2021, two major series have been published on mucormycosis of faciomaxillary/paranasal sinuses, with a reported frequency of orbital involvement in 66.7% and 43.5% cases, respectively. In the former multi-centre study, 18 patients with maxillofacial/rhino-cerebro-orbital mucormycosis who were COVID positive and received steroids were analysed. Sixteen patients were poorly controlled diabetic. All the patients were started on liposomal amphotericin B. Loss of vision was noted in 12 of 18 patients (66.7%) out of whom 7 underwent exenteration. Ophthalmic details were not available in the study. Sinus debridement was done along with maxillectomy in 11 patients. Mortality was in six patients and one patient was lost to follow-up. In the latter series of 23 patients, with paranasal sinuses mucormycosis with concomitant COVID-19 infection, authors reported orbital involvement in ten patients (43.5%), none of them had vision loss indirectly suggestive of mild or subtle orbital involvement. The authors did not provide any other ophthalmic clinical and imaging details. None of the patients in their series underwent exenteration, though two patients were administered intra-orbital amphotericin B. All patients underwent surgical debridement. Twenty one patients were diabetic and all 23 patients had used steroids for control of COVID-19 infection. There were no mortalities. This study analyses and restricted travelling led to a surge in cases with uncontrolled diabetes. These could have been the probable reasons for the recent onset of diabetes in two of our patients. Various mechanisms have been proposed for the increased risk of COVID-19 amongst diabetic patients, which include impaired macrophage and neutrophilic activity, and cytokine storm.

The most accepted mechanism is, however, the efficient entry of the virus into the cells through ACE 2 receptors expressed in a large number of organs, such as lungs, kidneys, and pancreas. The entry of the virus is facilitated in the pancreas, causes damage and an impaired insulin secretion leading to a state of hyperglycemia. Further, the use of steroids for the management of the lung infection in COVID-19, have led to a deterioration of diabetic status.

All our patients had advanced orbital disease probably because of the fulminant and rapidly progressive nature of the disease in uncontrolled diabetics. Patients presented to us with a mean duration of ocular symptoms, 10.4 ± 2.2 days (range 5–25 days). Ours being a referral centre could be one of the reasons for the late presentation of the patients. Further, lockdown, fear of acquiring COVID infection and a major shift in the health care system for control of COVID-19 pandemic were probably some important factors for delayed presentation.

The standard treatment for a necrotizing infection is wide surgical debridement i.e., removal of all necrotic tissues till healthy margins along with medical management. Most of the necrotizing infections, bacterial or fungal, are generally due to the highly virulent angio-invasive nature of the organism, which spreads fast leading to high morbidity and mortality, especially in immunocompromised individuals. Further, drug penetration is extremely poor within the necrosed tissues, so early and wide debridement is imperative to control the infection. Our decision for exenteration was made based on the extent of orbital involvement, the systemic status of the patients, and the overall prognosis. Clinically, presence of moderate to severe proptosis, significant resistance felt on retropropulsion test, total ophthalmoplegia with no vision, supported by imaging findings of diffuse involvement of orbital tissues, extending till apex indicated advanced form of infection. We performed exenteration along with sinus surgery in 12 of 15 patients and all the patients survived till mean follow up of 4.8 ± 0.83 months (4–6 months).

Dependin on the extent of orbital disease, few reports are available on direct drug delivery methods of amphotericin B and/or selective debridement of the orbital necrotic tissue in patients with orbital disease in cases with ROM. In the latter series of 23 patients, with paranasal sinuses mucormycosis with concomitant COVID-19 infection, authors reported orbital involvement in ten patients (43.5%), none of them had vision loss indirectly suggestive of mild or subtle orbital involvement. The authors did not provide any other ophthalmic clinical and imaging details. None of the patients in their series underwent exenteration, though two patients were administered intra-orbital amphotericin B. All patients underwent surgical debridement. Twenty one patients were diabetic and all 23 patients had used steroids for control of COVID-19 infection. There were no mortalities. This study probably suggests that early detection and control of mucormycosis of paranasal sinuses and nasal cavity can help in the control of orbital infection thereby preventing its progression to an advanced stage of orbital disease and hence the need for exenteration and further spread to the brain.

Patients with uncontrolled diabetes are, as such, prone to ROM due to impaired phagocytic activity of macrophages and neutrophils. Further, hyperglycemia, the release of iron, hypoxic environment, acidic pH and raised ketones, especially in patients with ketoacidosis are the factors that make the disease invasive and rapidly progressive.

During the first wave of the COVID-19 pandemic, lack of non-COVID facilities in the hospital, non-compliance to medications, lack of physical activities, paucity in daily exercises and restricted travelling led to a surge in cases with uncontrolled diabetes. These could have been the probable reasons for the recent onset of diabetes in two of our patients. Various mechanisms have been proposed for the increased risk of COVID-19 amongst diabetic patients, which include impaired macrophage and neutrophilic activity, and cytokine storm. The most accepted mechanism is, however, the efficient entry of the virus into the cells through ACE 2 receptors expressed in a large number of organs, such as lungs, kidneys, and pancreas. The entry of the virus is facilitated in the pancreas, causes damage and an impaired insulin secretion leading to a state of hyperglycemia. Further, the use of steroids for the management of the lung infection in COVID-19, have led to a deterioration of diabetic status.

All our patients had advanced orbital disease probably because of the fulminant and rapidly progressive nature of the disease in uncontrolled diabetics. Patients presented to us with a mean duration of ocular symptoms, 10.4 ± 2.2 days (range 5–25 days). Ours being a referral centre could be one of the reasons for the late presentation of the patients. Further, lockdown, fear of acquiring COVID infection and a major shift in the health care system for control of COVID-19 pandemic were probably some important factors for delayed presentation.

The standard treatment for a necrotizing infection is wide surgical debridement i.e., removal of all necrotic tissues till healthy margins along with medical management. Most of the necrotizing infections, bacterial or fungal, are generally due to the highly virulent angio-invasive nature of the organism, which spreads fast leading to high morbidity and mortality, especially in immunocompromised individuals. Further, drug penetration is extremely poor within the necrosed tissues, so early and wide debridement is imperative to control the infection. Our decision for exenteration was made based on the extent of orbital involvement, the systemic status of the patients, and the overall prognosis. Clinically, presence of moderate to severe proptosis, significant resistance felt on retropropulsion test, total ophthalmoplegia with no vision, supported by imaging findings of diffuse involvement of orbital tissues, extending till apex indicated advanced form of infection. We performed exenteration along with sinus surgery in 12 of 15 patients and all the patients survived till mean follow up of 4.8 ± 0.83 months (4–6 months).

Dependin on the extent of orbital disease, few reports are available on direct drug delivery methods of amphotericin B and/or selective debridement of the orbital necrotic tissue in patients with orbital disease in cases with ROM.

Disclosure of competing interest

The authors have none to declare.
REFERENCES

1. Shinde RV, Karande CS, Mohite ST, Patil SR. Rhino-orbital mucormycosis in diabetes mellitus. J Clin Diagn Res. 2013 Jun;7(6):1145–1147. https://doi.org/10.7860/JCDR/2013/5528.3083.

2. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019 Mar 21;5(1):26. https://doi.org/10.3390/jof5010026.

3. Pagano L, Offidani M, Fianchi L, et al. GIMEMA (gruppo italiano malattie EMatiche dell'Adulti) infection program. Mucormycosis in hematologic patients. Haematologica. 2004 Feb;89(2):207–214.

4. Patel AK, Patel KK, Patel K, Gohel S, Chakrabarti A. Mucormycosis at a tertiary care centre in Gujarat, India. Mycoses. 2017 Jun;60(6):407–411. https://doi.org/10.1111/myc.12610.

5. Spellberg B, Ibrahim AS. Recent advances in the treatment of Mucormycosis. Curr Infect Dis Rep. 2010 Nov;12(6):423–429. https://doi.org/10.1007/s11908-010-0129-9.

6. Luna JD, Ponssa XS, Rodriguez SD, Luna NC, Juarez CP. Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis. Ophthalmic Surg Laser. 1996 Aug;27(8):706–708. PMID: 8858637.

7. Gupta S, Goyal R, Kaore NM. Rhino-orbital-cerebral mucormycosis: battle with the deadly enemy. Indian J Otolaryngol Head Neck Surg. 2020 Mar;72(1):104–111. https://doi.org/10.1007/s10707-019-01774-z.

8. Sen M, Lahane S, Lahane TP, Parekh R, Honavare SC. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021 Feb;69(2):244–252. https://doi.org/10.1016/j.ijo.2020.3774.20.

9. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021 Apr;69(4):1002–1004. https://doi.org/10.1016/j.ijo.2020.3763.20.

10. Ravani SA, Agraval GA, Leuva PA, Modi PH, Amin KD. Rise of Mucormycosis in hematologic patients. J Diabet. 2017 Jun;31(12):1109–1114. https://doi.org/10.2337/diabcare.31.12.1109.

11. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholly trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6;1–8. https://doi.org/10.1007/s12663-021-01532-1.

12. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: an initiative of the European confederation of medical mycology in co-operation with the mycosis study group education and research consortium. Jaryngol Otol. 2021 Apr 8:1–6. https://doi.org/10.1016/j.iijo.2021.310.21.

13. Poyser A, Deol SS, Osman L, et al. Impact of COVID-19 pandemic and lockdown on eye emergencies. Eur J Ophthalmol. 2021 Jun;69(6):1563–1568. https://doi.org/10.1016/j.ejo.2020.310.21.

14. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):535–545. https://doi.org/10.1016/j.dsx.2020.04.044.

15. Orio I, Hermans MP, Thiessen JP, Maiter D, Vandeleene B, Yombi JC. COVID-19 in diabetic patients: related risks and specifics of management. Ann Endocrinol (Paris). 2020 Jun;81(2–3):101–109. https://doi.org/10.1016/j.anedt.2020.05.001.

16. Yang Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care. 2020 Apr;8(1), e001343. https://doi.org/10.1136/bmjdrcc-2020-001343.

17. Marelli S, Castelnuovo A, Somma A, et al. Impact of COVID-19 lockdown on sleep quality in university students and administration staff. J Neurol. 2021 Jan;268(1):8–15. https://doi.org/10.1007/s00415-020-10056-5.

18. Füzéki E, Groneberg DA, Banzer W. Physical activity during COVID-19 induced lockdown: recommendations. J Occup Med Toxicol. 2020 Aug 12;15:25. https://doi.org/10.1186/s12995-020-00278-9.

19. Abdi A, Jalilian M, Sarbarzeh PA, Vlasavljecic Z. Diabetes and COVID-19: a systematic review on the current evidences. Diabetes Res Clin Pract. 2020 Aug;166:108347. https://doi.org/10.1016/j.diabres.2020.108347.

20. Kamar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Metab Syndr. 2020 Sep 17;14(4):93–99. https://doi.org/10.1017/mss.2020.109.

21. Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19 associated with mortality and severity of COVID-19. BMC Immunol. 2020 Nov 19. https://doi.org/10.1186/s12910-020-00559-6.

22. Cornely OA, Aalstuever-Izquierdo A, Arnez D, et al. Mucormycosis: ECMM MSG global guidelines writing group. Global guidelines for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in co-operation with the mycosis study group education and research consortium. Lancet Infect Dis. 2019 Dec 19;19:4065–4071.

23. Seiff SR, Choo PH, Carter SR. Role of local amphotericin B therapy for sino-orbital fungal infections. Ophthalmic Plast Reconstr Surg. 1999 Jan;15(1):28–31. https://doi.org/10.1097/00001081-199901000-00007.

24. Hirabayashi KE, Kailin-Hajdu E, Brodie FL, Kersten RC, Russell MS, Vageh MR. Retrobulbar injection of amphotericin B for orbital mucormycosis. Ophthalmic Plast Reconstr Surg. 2017 Jul;33(4):e94–e97. https://doi.org/10.1097/IOP.0000000000000856.

25. Songu M, Unlu HH, Gunhan K, Iker SS, Nese N. Orbital exenteration: a dilemma in mucormycosis presented with orbital apex syndrome. Am J Rhinol. 2008 Jan-Feb;22(1):98–103. https://doi.org/10.2500/ajr.2008.22.3121. PMID: 18284868.